Dr. Taiyin Yang has more than four decades of experience in developing and manufacturing medicines in several therapeutic categories. She worked at Gilead Sciences for 29 years, serving as executive vice president of Pharmaceutical Development and Manufacturing with responsibility for all the company’s investigational compounds and marketed products from 2015 until her retirement in 2022. Under Dr. Yang’s leadership, Gilead developed the world’s first HIV single tablet regimen and advanced more than 25 compounds from early-stage development to commercialization, reaching millions of people around the world. Earlier in her career, Dr. Yang worked at Syntex Corporation, contributing to the development and commercialization of more than 10 medicines.
In addition to Kronos Bio, Dr. Yang is currently a member of the board of directors of Kodiak Sciences and is a member of the Expert Scientific Advisory Committee of Medicines for Malaria Venture. In 2021, Dr. Yang was elected a fellow of the American Institute for Medical and Biological Engineering.
Dr. Yang has a B.S. in chemistry from National Taiwan University and a Ph.D. in organic chemistry from the University of Southern California.